

The Triad Wins Again! Know-How Leads Us to Cancer-Busting Technology and a Mysterious Stock That's Set to Soar

Plus: A Homeless Lover Learns a Lesson... And Add These Cancer-Fighting Foods to Your Diet Today

Dear Reader,

We all know the opening lines to the iconic hymn *Amazing Grace*.

About halfway through the first verse, we hear a powerful message.

“I once was lost, but now am found.”

What a refreshing line... and not just for the folks who head to church on Sunday mornings.

The idea applies to so much in life.

Religious experiences? For sure. But what about knowledge?

I once was lost... but now I know.

It reminds me of a story I penned several months ago. It was about a man named John Martin III.


He's a homeless man from Soldotna, Alaska, who fell in love.

After living with his wife in China for several years, he was sent back to the U.S. He was lost without her.

So he did what any crazy man would do. He hopped into an 8-foot dinghy and set sail across the frigid and windy Bering Sea.

As we'd expect, he got lost.

But don't worry... the Russians found him.



Two weeks after shoving off a stone-laden beach in southern Alaska, he ended up in the rolling surf off the country's Chukotka Peninsula.

John had no money... no passport... and no documents with him.

The Russians, of course, tossed him in jail.

His friend posted this message from John online:

I am now at the detention center in Moscow. It can best be described as a prison. I have two cell mates, one from Australia, the other from Turkey. We are locked in our cells 23 hours each day, with one hour let out each day in a caged area. I don't know when they will deport me.

John was lost...

I bet he wished he had a bit more knowledge before heading out to sea. Even a compass could have helped him avoid his painful fate.

LIBERTY



KNOW-HOW



CONNECTIONS



But that's the way it goes with our old pal Know-How.

By the time we bother to give him a call, it's too late.

Finding Our Way

We're all born lost. Outside of our instincts, we start with nothing. With each passing day, it's up to us to continue adding to our breadth of knowledge.

It's simple when we're kids. Everything is new. The basics are easy to learn.

But picking up anything new – at least anything worthwhile – is hell as we age.

Even in this so-called "Information Age," it's oh so easy to get lost.

Take our health, for instance.

I recently strolled into the local hospital's oncology wing. We visited one of the best men we've ever known. He doesn't have long.

Neither does his roommate. He has liver cancer.

His spirits were good.

But we wondered if he was optimistic or just ignorant.

Both make us feel the same – at least in the short term. But ignorance is a cruel enemy. He'll convince us we're safe. But one night he'll sneak in, put a bag over our heads and carry us off to a dark and scary place.

Only the light of Know-How will keep him at bay.

The Lighthouse in the Distance

Again, we turn to that crazy man who pushed his boat out to sea.

If only he had studied his route... had understood sea currents... and had bothered to know what Russians tended to do to Americans like him.

It would have saved him nearly a year of agony.

But believe it or not, the story has come to an end. The conclusion is quite predictable.

John has found his way home. A friend in Virginia vouched for him and paid his way back to the States.

And now, after that long, painful journey, our lovesick sailor is right back where he started. He's back on the streets of Alaska.

That's no way for a person to live... at least not if they want to get where they ought to go.

The lost, we say, should always be found.

The unknown must become the known.

As I picked up my pen this month, that's the idea I had in mind. We're focusing entirely on our Know-How. And, more precisely, we're focusing on how it relates to our health.

Take, for example, that man with liver cancer.

I couldn't stop thinking of him as I walked across the hospital's icy parking lot. While he's suffering from the pain that comes with modern radiation and chemotherapy, does he know that the best cure for cancer is to never get it in the first place?

It sounds glib. But we dare you to argue the point.

We'd much rather zap our minds with Know-How today than zap our organs with electrons tomorrow.

Does that poor, tired man, for instance, know that doctors are now starting to believe our zip code plays a larger role in our defense against cancer than our DNA?

Does he know that adding just a few things to his diet could have added years to his life?

I fear it's too late for him.

He's lost and may not be found in enough time.

But *you* still have hope. What you need can still be found.

Again, that's the idea I had in mind as I pulled this issue together and as I worked with Dr. Roberts on his experience-rich contribution.

In the first article, I detail a potential breakthrough in the realm of cancer research. It's fascinating. And it paints a true picture of the type of work some of the smartest folks in the country are doing each day.

This effort isn't being pushed by Big Pharma. It's not just another way to monetize our nation's ailments.



It's a potential cure.

One day soon, it may save the life of someone you know.

After that, I do what I've done for a long time now. I recommend a stock that so many others have overlooked. I used my Know-How to sniff out an opportunity in the healthcare industry that doesn't get all that much attention... and yet it's growing at an unrivaled clip.

And finally, Dr. Roberts shares his wisdom on fighting cancer from the inside out.

So before we get into it, I'll say it again.

We've all been lost. In many ways, we all still are.

But our Know-How will guide us to where we need to go.

I hope the words ahead serve as a great compass.

Be well,

Andy

Stunning Breakthrough in Cancer Prevention... With a 100% Success Rate

I have a very good friend who's suffered from several types of cancer. She beat breast cancer. But she's still working on her skin cancer.

About twice each year, she heads to the dermatologist for a checkup. And each time, she leaves the office in pain, with bandages covering various parts of her body.

The doc cuts out chunks of cancer every visit.

It's an ongoing game of whack-a-mole. One cluster of cancerous cells is chiseled away from her leg... just as another group pops up on her neck. It's been this way for several years.

It's the result of a lack of Know-How when she was young. Sunscreen could have prevented all of this.

But there's growing hope that the next time she pulls into the doc's parking lot, she'll drive away with little more

than a Band-Aid on her upper arm and the promise of being cancer-free... for good.

That's right. For at least one type of deadly cancer, there's fresh research that shows a vaccine may be saving lives sometime soon.

Right now, the tests have been confined to lab mice.

But the results are stunning.

There have been several successful studies of this kind, but the latest comes to us from the folks at the Scripps Research Institute in California.

Their study focused on a current treatment for melanoma that aims at our immune system's response to cancer. It's called anti-PD-L1.

It works... but it's not great.

It's certainly not a cure. I found that about 40% of melanoma patients have a valid response to the treatment.

Given the immunotherapy's current lackluster results but perceived potential, the scientists at Scripps set out to see if there was a way to boost the treatment's success rate.

That's where the rats come in.

Miracle: The Cancer "Wouldn't Take"

The docs divided a group of 24 mice into three categories. All three groups were given the anti-PD-L1 treatment. From there, one group was given a vaccine that had recently shown clinical success. Another group was given the vaccine plus a chemical known as alum. And the third group was treated with the vaccine plus a molecule called Diprovocim.

The results were stunning.

The mice that received the immunotherapy treatment plus the plain vaccine died – all of them.

Of the mice that got the vaccine and the alum, only 25% lived.

But of the mice that got the special molecule along with the vaccine... every one lived. It was a 100% success rate.

"This co-therapy produced a complete response – a curative response – in the treatment of melanoma," said



Dr. Dale Boger, who co-led the study.

That's huge. But the story doesn't end there.

The mice that survived the test weren't done yet. The docs had something bigger planned for them.

The curious scientists wanted to try the test again. They tried to reintroduce melanoma into the mice.

But guess what?

"It wouldn't take," Dr. Boger said. "The animal is already vaccinated against it."

A Shot in the Arm

It turns out that this new vaccine works inside our bodies in much the same way as a flu shot. It trains our body to go after the invaders. In this case, with the help of Diprovocim, the mice's immune systems produce special cancer-busting cells called leukocytes.

Once the body learns how to do this, scientists think it is nearly impossible for cancers like melanoma to form.

Imagine that. **It means a cancer-preventing vaccine could be on the way.**

That certainly appears to be the case with the vaccine trials from Scripps. The docs there believe just two injections a week apart could prevent melanoma and possibly other forms of deadly cancer.

Of course, you won't be seeing ads for this new drug on TV or in your favorite magazine anytime soon. It still needs a slew of human trials and Washington's coveted stamp of approval before it hits the market.

But there's hope. This is a big breakthrough.

Beating the Odds

It's important that I tell you this treatment is different from other cancer vaccines you may soon hear about.

If you pay attention to medical news, you've likely heard of a bit of a breakthrough early last year.

As you read this, scientists at Stanford University are testing a promising lymphoma treatment on 15 folks. This treatment also comes in the form of a vaccine and stimulates the body's immune system to attack cancer cells.

In rodent trials, the treatment eradicated lymphoma, breast and colon cancer tumors in 87 out of 90 mice. And it worked even after the cancer spread.

It shows great hope.

But there are a couple of caveats.

First, while this treatment works much like a vaccine, it doesn't fit the true definition of the word. Unlike the huge trial out of Scripps, the Stanford study doesn't show any preventive abilities.

It could still save lives, but it's not the dream cancer preventer that is the medical industry's holy grail.

The other caveat applies equally to both vaccines. Just because the vaccines worked well for mice doesn't mean they will work well on you and me. Docs have been able to cure some forms of cancer in mice for a long time. The treatments rarely work as well in our more complex bodies.

But still... this is big progress.

The curious health researcher in me can't help but be giddy. **And the investor in me is drooling over the potential.**

That's another vital point to understand.

Big Pharma Be Damned

I've been studying treatments like these for close to 20 years. Very often some of the most eye-catching breakthroughs aren't made by huge, publicly traded companies. They're made in university laboratories or spinoffs owned by the professors who work at them.

That's the case with the molecule that's drawing so much speculation as a potential melanoma cure. Diprovocim is being developed by a small company called Tollbridge Therapeutics.

Don't get your hopes up, though. It's not publicly traded.

In fact, it's managed and run by a small group of doctors and investors... including Dr. Boger, whom I mentioned above.

For investors, that's not great news. If Diprovocim turns out to be the next big thing... you won't be one of the investors who get rich from it.



But if you're suffering from cancer, well, that's another story. The fact that this tiny company is owned by just a few investors is good news... fantastic news, in fact.

I'm on record saying that I truly don't believe some of the folks in Big Pharma are all that excited to bust cancer. It's a dangerous and loaded idea, but I'm convinced that they've too often put profits above health... and that if a simple vaccine could wipe out the multibillion-dollar-per-year cancer industry, they would think twice about making it public.

It'd be hell on share prices.

Some say it would wipe \$10 billion worth of sales right out of the economy.

With this Stanford study, for example, several analysts have already touted the dire effects it would have on immunotherapy companies like **Incyte** (INCY) and **Celldex** (CLDX). Even a diversified behemoth like **Roche** (RHHBY) could be hit. After all, its lymphoma drug is one of the world's top-selling cancer treatments.

Its days would be numbered if a cure-all cancer vaccine hit the markets.

I hope you're seeing the inherent conflict these companies face.

They profit from treating cancer... not curing it.

But that's not the case for Tollbridge. It has very little on the line. In fact, for it, it's all upside.

Getting a vaccine to market would take the tiny firm from startup to behemoth almost overnight.

The Best Cure

The lesson to take away from all of this is quite straightforward.

It's what I came across time after time while putting together my new book, *Nature's Miracles*.

The truth is... for all of our research, the vast sums of money and a behemoth industry behind it all, we still don't know what really makes the human body tick.

We've got some good clues, but we certainly don't have it all figured out.

But nature does. She's just not giving up her secrets.

That's why I urge you to focus intently on your Know-How... learn everything you can... and don't take your doctor's word just because he's the one in the lab coat. Your doc certainly means well, but his knowledge is only as vast as his time and resources allow.

Yes, science is advancing every day. But don't bet your life on it.

As I said in my opening essay, there are things in your control that impact your chances of cancer, including where you live and what you eat.

So instead focus on putting the very best things into your body and keeping the harmful substances out.

Treat food like a preventive vaccine you can take daily to give yourself the best outlook.

As a subscriber, you have free access to my new book. I urge you to check it out and study some of the most promising natural treatments available to us today.

Combined with the breakthroughs from the medical world, there is serious hope.

It's a great time to be alive.

THIS MONTH'S STOCK PICK

Andy Snyder has made his followers rich. After leaving one of the nation's leading brokerages, Andy decided to take his wealth-exploding advice to the masses. Using his nearly two decades in the investing business, he provides clear and easy-to-follow guidance on the best stocks to invest in each month in Manward Letter.

Easy Win: Three Times the S&P for the Next Five Years

This may be one of my most controversial stock picks... ever.

But if you pay attention and keep an open mind, you'll see that it proves good health isn't merely about you and me.

In nearly 20 years in the business, I've never researched a company with as much mystery... as much potential to



polarize... as many myths and half-truths surrounding it... and such rich power to evoke emotion.

That said... **I've rarely seen anything that can go higher with as much speed and reliability.**

Any economist will tell you that one of the simplest ways to quickly gauge the financial health of a nation is to look at the way it treats its animals.

If it eats them... times are tough.

If it carries them around in plush, bedazzled carriers while traveling in first class... indeed, times are grand.

Stroll through an airport these days and you'll quickly see which way America leans. Some days when I fly, it's hard to know if I'm strolling through an airport or an upscale kennel.

But what led me to my latest discovery was when several readers wrote to me recently about my research on cannabidiol.

I was writing about its immense ability to reduce pain.

But the readers didn't care about their own pain.

They wanted to know how they could use the newly legalized and rather expensive medicine to ease their dogs' discomfort.

With some quick research, I realized something I'd been missing. It hit me like most good ideas hit me.

"Why didn't I think of that before?" I said to myself. "It's obvious."

That's how I uncovered a stock that you must absolutely own.

It's an obvious "best of class" choice for our prized **Own What You Know Portfolio.**

How Dare You?!

If you've followed my work, you likely know that my family and I recently moved from one small farm to a bigger, but still small, farm.

The new place could best be described as a gentleman's farm. It's 35 acres or so of rolling hills, walnut-filled woodlots and a creek that's quite confused about where it wants to go.

And, of course, farms have animals.

Over the years, we've had a lot of them. We figure it's a good way to raise a family. And it ensures we never get so bored that we dare turn on the TV.

But no matter how green our pastures, how clean our water or how naturally we care for our animals (we think they're living in luxury)... they get sick.

Fortunately, we've never had to give our animals much medicine. And we never inject them with drugs just to make them grow faster or fatter (the controversial side of the stock I'm about to tell you about).

But farm animals are no different from you and me. Sometimes they get sick and need a little help.

That's when we give them a dose or two of medicine – something uninformed so-called conscious consumers often (and ignorantly) find abysmal.

RETIREEES: If You Own Large Cap Stocks, Read THIS

Large caps like Microsoft and Procter & Gamble should be in every investor's portfolio. They're a reliable way to build wealth... slowly.

But if you want fast profits, there's a new way to make up to **\$11,505 every week.**

To learn how, go to **www.manwardtrader10.com**. Or call **844.201.1980** or **443.541.4636** and mention priority code **GMTDV300** to take advantage of this special offer.



A Vet in the Field

You'd be surprised to know that there aren't a whole lot of choices when it comes to who to get the medicine from... especially if you want quality and effectiveness you can trust.

Much of the medicine we've bought comes from a company that's not a household name.

Unlike some of the companies responsible for Big Ag's often deserved bad reputation, **Zoetis Inc.** (ZTS) is a veteran in the space that has never had a scandal exposed on *60 Minutes*... never been put under a congressional microscope... and never been caught in a nasty cover-up.

Yes, it makes some products that make us raise an eyebrow, but only the naïve would go so far as to believe our world and our health would be better off without a company like Zoetis and its investors.

After all, if we want to eat cheap food and maintain a burgeoning global population... we definitely need Zoetis.

The company is divided into two main categories – farm animals and companion animals (aka pets).

But before I explain the growth potential in both areas, it's important you have a bit of background on the company.

After all, it's been around for a long time... but it isn't that old.

You see, Zoetis is the child of a much bigger company – **Pfizer** (PFE).

After the division got so big, Pfizer spun off the animal-care line. It was one of the biggest IPOs of 2013. The size of the deal, in fact, rivaled Facebook's initial stock market debut.

Pfizer has long been known as an income stock. In fact, its stock has barely budged over the last decade, but its dividend has been strong and steady.

That's why shareholders cheered when the company announced it would be sending Zoetis out on its own.

It allowed Pfizer to continue to do what it does best, and it freed one of its quickest-growing business lines to do what it does best... grow.

That's exactly what's happened.

No Artificial Hormones Necessary

Since the separation from Pfizer five years ago, Zoetis has grown its business by nearly 50%. Put another way, it's grabbed some \$1.6 billion in additional sales.

Sales at its former parent company, on the other hand, are virtually flat.

From here, I'm focused on two major growth catalysts.

Within the company's ag lineup, the story is all about international expansion. And because farming is not all that dependent on economic growth, good news from this business line does not hinge on the health of the global economy.

Instead, it hinges on the growth of the global population.

It's no secret the world's population is booming. And that means we need more food... particularly in the poorest corners of the globe.

That's where Zoetis sees its greatest potential.

Take, for example, the work it's doing in sub-Saharan Africa. It comes thanks to a \$14 million grant from the Bill & Melinda Gates Foundation.

The region is home to some of the world's largest livestock herds and yet has some of the poorest farmers. They're just now learning about and getting access to the products they need to keep their animals healthy.

This three-year deal is one of the best examples I've seen of the value of a company like Zoetis working within the immense life-changing power of a capitalist system.

For Profit... and for Good

When Zoetis brought its knowledge and technology to Uganda and Nigeria, the region's farmers immediately saw the benefit. Their animals were healthier, and their food systems were safer and more reliable.

As farmers realized the value of its products, Zoetis realized it needed to create a distribution system. It quickly set up a supply chain.

It created jobs. And now that things are maturing, the company has itself a brand-new region in which to sell its products.



But the vital thing to understand is not only does Zoetis benefit, but so do the farmers and the people in southern Africa.

Thanks to Zoetis and its products, they now have a safer, more efficient source of food.

It's capitalism at its finest.

As we'd expect from a company like this one, Zoetis offers its agricultural customers a wide array of products in a wide array of locations.

It researches, manufactures and sells everything from diarrhea medicine for cows and pneumonia treatments for pigs to antibiotic treatments for animals that get sick. And it sends its products to more than 100 different countries.

As the world's demand for food grows (it's perhaps one of the most reliable trends on the planet), so will demand for these products.

But remember, I said that Zoetis' share price appreciation hinges on two growth channels.

The ag sector is one of them... and the company's companion animal business is the other.

Thanks, Fido!

Like I said, one of the simplest measures of a country's economy is how it treats its pets. And while we so often focus time and money on medical breakthroughs related to things like cancer, heart disease and Alzheimer's, we can't overlook the vast amount of money Americans spend on pet health each year.

It's a bit insane.

According to a fresh report from the American Pet Products Association (APPA), **our nation now spends more than \$70 billion each year on our pets.** That figure is growing at more than twice the growth rate we're seeing within the global ag industry.

Again, it's a bit insane.

More specific to Zoetis, though, spending on veterinary care has hit the \$17 billion mark... and it's growing at nearly four times the rate of the global ag industry's spending.

So forget cancer, heart disease and the rest... If you want to find the nation's hottest healthcare sector, just look to Fido.

"Talk to any pet owner and they'll tell you how difficult it is to put a dollar limit on what they'd spend to give their loyal companion a happy life," said Bob Vetere, president and chief executive officer of APPA, "and it's this outlook that continues to drive growth."

It's fantastic news for Zoetis – whose name, by the way, roughly translates to "pertaining to life."

It's a leader in veterinary medicine.

It sells everything from anti-itch cream for cats to flea medicine for dogs (ask me sometime about how I once caught fleas) and even a vaccine called Zylexis, which helps horses fight upper respiratory infections.

If it's true that pet lovers can't put a price tag on the health of their best friends, perhaps I shouldn't bother to predict just how high shares of Zoetis will climb.

But being a free market believer, I know that everything has its price (sorry, Fido). Fortunately, that price is often quite high.

Three Times the S&P

In this case, I'm convinced shares of Zoetis will surge at an average annual rate of more than 20% over the next five years.

That's a huge figure for such a conservative, low-risk stock. But it actually represents a slowdown compared with the more than 25% average annual growth rate we've seen since the company's epic IPO in 2013.

I'm excited about this play.

It's our chance to more than triple the market's average annual return... with a very conservative stock.

The company sells products that I use and know well. If you have a pet or are like me and have a few barnyard critters, you likely do as well.

But what's most important is that more and more folks across the planet are using its products. They're a requisite ingredient in feeding the growth of our planet.

Plus, by owning some shares, you'll be much more understanding the next time you sit down on a long



flight... and have a fluffy white dog hogging the aisle seat beside you.

Big things are happening in the world of health... and they're not all aimed at fixing up you and me.

Fido needs to feel good too.

Action to Take: Buy shares of **Zoetis Inc.** (NYSE: ZTS) at market. When you do, immediately enter a 25% trailing stop.

Dr. Phil Roberts is a renowned and sought-after expert in anti-aging functional and regenerative medicine and is board-certified in emergency medicine. He shares his insights each month on our healthcare system, patient care and how to achieve optimal health.

Add These Cancer-Fighting Foods to Your Diet Today

By Dr. Phil Roberts, MD

Here's a sobering statistic: 50% of men will develop cancer in their lifetime... as will 40% of women.

Cancer is in a race with heart disease to become the No. 1 killer in America.

These days, it's unusual **NOT** to have had one or more family members die from this dreaded disease.

To put it mildly, understanding the causes of cancer has been a complex and frustrating problem for decades.

However, we do know free radicals play a significant role.

These are unpaired electrons in broken-down oxygen molecules that seek out other electrons to pair with. (This process is called oxidation.)

The unpaired electron grabs another from whatever cell is closest to it.

Their pairing creates havoc, damaging and destroying the unsuspecting nearby cells.

There are many reasons free radicals form. (And I should say that not all free radicals are bad. In fact, some are very good for us.¹)

Some of the top triggers include our genetics, environmental factors, processed foods, **nutrient deficiencies**, contaminated water and toxic chemicals.

Over time, damaged cells can begin to divide uncontrollably. This uncontrolled cell growth is the foundation of cancer.

The rapidly forming cells become tumors.

When our body is unable to fight off this process, there are deadly consequences.

Fortunately, it is possible to slow or reverse the oxidative process that leads to cell destruction... and cancer.

You simply need to feed your body antioxidant-rich foods or supplements, foods that give free radicals what they need to function in a healthy way in your body.

Eat Your Veggies

Vegetables are a fantastic source of antioxidants, phytonutrients (nutrients that lower inflammation, helping to prevent cancer) and carotenoids (also inflammation fighters).

These nutrients have the ability to alter genes... changing their destructive tendencies to healthy behaviors.

That's right; you *can* turn off and on genes that lead to cancer.²

So let's load up your plate with the best cancer-fighting foods out there.

Cruciferous vegetables in the Brassica family lead the way in producing compounds that are protective of the body. Broccoli, Brussels sprouts, bok choy, cabbage, cauliflower, collard greens, kale, mustard greens and turnips are many of the stars here.

Brassica veggies contain glutathione, which is the master antioxidant of the body. They also provide a family of chemicals that prevent improper estrogen breakdown.

This is hugely important in preventing many types of breast and prostate cancers.³



These veggies should be eaten raw or steamed. They also make a tasty treat when *lightly* stir-fried in olive oil or coconut oil.

Berries and fruits are powerful antioxidant allies. My favorites include Gogi berries, black raspberries, prunes, pomegranates, bilberries, strawberries, blueberries, red raspberries, cherries and plums.

These all-stars are high in vitamin C as well, which is an anti-viral and anti-cancer compound.⁴

Orange and yellow fruits and veggies high in carotenoids include carrots, sweet potatoes, squash and pumpkins. They also pull double duty in protecting your eyes, brain and skin.

Boost Your Immune System

Let's not stop at antioxidants. There are many nutrients that help strengthen your immune system, which – as you know – is crucial for fighting off any type of illness, let alone cancer.

So add to your plate foods high in vitamin D, selenium and zinc.

Vitamin D-rich foods include eggs (free range is best), meats (organic is best) and cremini mushrooms. You may also want to consider supplementing with vitamin D3.

Foods high in selenium include eggs, cheese, Brazil nuts, beef, chicken, pork and oysters. It is also easy to take 200 micrograms of selenium daily, which has been shown to help with prostate cancer prevention.⁵

Get your zinc intake from oysters, beef, chicken, pork, lentils and hemp seeds. Zinc helps protect DNA and repair cell damage.

Condiments, Please

Be sure to top off your cancer-fighting foods with a variety of spices.

Black pepper helps you absorb more nutrients. Use sea salt, as it contains 80 or so minerals and vitamins (the bleaching process for refined salt removes them).

Turmeric powder is also a great spice to add to foods for its anti-cancer properties. Not to mention thyme, basil, parsley and garlic.

A diet packed with cancer-fighting nutrients doesn't have to be boring, and the benefits could be lifesaving. Include some – or all – in your daily meals to give your body what it needs to support healthy free radicals.

Stop the cancer process before it starts, and help your body function at its optimal level.

References

1. "Vilified Free Radicals Boost Tissue Healing and Regeneration in Tadpoles (and Perhaps Humans)," *New Atlas*.
2. "Epigenetic Diet: Impact on the Epigenome and Cancer," *Epigenomics*.
3. "Can Diet and Lifestyle Prevent Breast Cancer: What Is the Evidence?" *American Society of Clinical Oncology Educational Book*.
4. "Vitamin C and Cancer Prevention: The Epidemiologic Evidence," *The American Journal of Clinical Nutrition*.
5. "The Association Between Selenium and Prostate Cancer: A Systematic Review and Meta-Analysis," *Asian Pacific Journal of Cancer Prevention*.

News That Scares Us

Leaky Vaccines

Did you know there are two types of vaccines?

One type is good. The other is quite dangerous.

As the name implies, "perfect" vaccines are good. They effectively prevent somebody from getting a disease, and they make it impossible for anybody to spread it.

The vaccines for smallpox, polio, mumps and measles are all "perfect."

That's good. Life would be hell if they weren't.

That's because the other type of vaccine, known as "imperfect" or "leaky," allows deadly pathogens to not only stay alive... but get stronger.

Think of it similarly to the problem we're having with antibiotic-resistant bacteria... just with viruses.

Right now, the biggest threat is to our food supply - particularly chickens.



Take the bird flu, for instance. Here in the States, when a chicken gets sick, the entire flock is typically culled. It effectively stops the spread.

But the approach in China is different – a lot different.

Folks there try to get ahead of viruses by using vaccines. And now there are growing worries about “superhot” strains of the avian flu taking hold in the region.

That’d be bad.

Countless chickens would have to be killed.

What’d be worse, though, is if the same trend trickled over to us humans. So far, it hasn’t been much of an issue. Like I said, the vaccines for our biggest killers destroy viruses and stop their spread.

But the future doesn’t look as bright.

Desperate to tackle killers like malaria, Ebola and HIV,

scientists are turning to imperfect treatments. They dramatically lower the effect of the disease but don’t stop its infection or its spread.

Some doctors are worried about the trend. They say we need to tread carefully as new “leaky” vaccines roll out.

One treatment that is getting particular scrutiny comes from GlaxoSmithKline. In use in three African countries, the vaccine Mosquirix seems to reduce malaria transmission only in kids. Even then, its effectiveness is well below 50% and plunges to just over 4% in less than seven years.

There’s no word of mutating malaria viruses yet, but forward-looking doctors tell the medical world to tread carefully.

We can cull a herd of chickens.

But the thought of culling humans because we took a few shortcuts is news that scares us. ■

The Everyman Portfolio

| Company/Symbol | Rec. Date | Rec. Price | Curr. Price | Rating | Trailing Stop | Total Gains |
|---|-----------|------------|-------------|--------|---------------|-------------|
| Assurant Inc. (NYSE: AIZ) | Apr-17 | \$95.11 | \$98.74 | Buy | \$81.78 | 7.92% |
| Braskem S.A. (NYSE: BAK) | Mar-18 | \$29.10 | \$29.29 | Buy | \$22.49 | 4.29% |
| CACI International (NYSE: CACI) | Feb-19 | \$172.51 | \$174.04 | Buy | \$131.72 | 0.89% |
| Constellation Brands (NYSE: STZ) | Dec-18 | \$193.21 | \$171.94 | Buy | \$142.77 | -10.63% |
| Golub Capital BDC (Nasdaq: GBDC) | May-18 | \$17.96 | \$18.05 | Buy | \$13.91 | 6.51% |
| ProShares Short FTSE China 50 ETF (NYSE: YXI) | Jan-19 | \$21.42 | \$19.23 | Buy | \$16.22 | -10.22% |
| ResMed Inc. (NYSE: RMD) | Oct-17 | \$76.53 | \$98.21 | Buy | \$88.04 | 31.15% |
| Waste Management Inc. (NYSE: WM) | Apr-17 | \$72.84 | \$98.65 | Buy | \$83.85 | 39.74% |

The Own What You Know Portfolio

| Company/Symbol | Rec. Date | Rec. Price | Curr. Price | Rating | Trailing Stop | Total Gains |
|--------------------------------|---------------|------------|-------------|------------|---------------|-------------|
| Alamo Group (NYSE: ALG) | Oct-18 | \$90.33 | \$87.03 | Buy | \$69.64 | -3.40% |
| Copart (Nasdaq: CPRT) | Nov-18 | \$50.30 | \$53.26 | Buy | \$39.95 | 5.88% |
| Visa (NYSE: V) | Sep-18 | \$147.80 | \$141.99 | Buy | \$112.89 | -3.76% |
| Zoetis Inc. (NYSE: ZTS) | Mar-19 | New | New | Buy | 25% TS | New |

* Based on Official Sell Date


as of 2/12/19




Appendix

About the cover image:

This 3D rendering of a cancer cell shows a white blood cell called a leukocyte attacking it. The promising vaccine we talk about helps the immune system grow these special cancer fighters when the vaccine is combined with the chemical compound Diprovocim. It's a stunning development that scientists are eager to try in other cancer therapies.



Zoetis Revenue Growth Rate Outperforms Industry Growth Rate



Thanks, Fido: Zoetis Revenue by Species

| | (Millions of Dollars) | Three Months Ended | | Nine Months Ended | |
|---|-----------------------|--------------------|----------------|-------------------|----------------|
| | | 9/30/18 | 10/1/17 | 9/30/18 | 10/1/17 |
| Livestock | | | | | |
| Cattle | | \$417 | \$424 | \$1,229 | \$1,192 |
| Swine | | \$160 | \$147 | \$500 | \$455 |
| Poultry | | \$130 | \$119 | \$395 | \$357 |
| Fish | | \$46 | \$39 | \$92 | \$79 |
| Other | | \$25 | \$25 | \$66 | \$63 |
| | | \$778 | \$754 | \$2,282 | \$2,146 |
| Companion Animal | | | | | |
| Dogs and Cats | | \$653 | \$546 | \$1,832 | \$1,561 |
| Horses | | \$35 | \$34 | \$117 | \$104 |
| | | \$688 | \$580 | \$1,949 | \$1,665 |
| Contract Manufacturing and Human Health Diagnostics | | \$14 | \$13 | \$30 | \$36 |
| Total Revenue | | \$1,480 | \$1,347 | \$4,261 | \$3,847 |

Source: Company Reports

Further Reading

“This Man Is Crazy... Crazy Smart,” *Manward Digest*: <https://manwardpress.com/featured-post/man-on-inflatable-dinghy-is-crazy-crazy-smart>

“A New Cancer Vaccine Shown to Be 100% Effective in Mice With Aggressive Melanoma,” *Science Alert*: <https://www.sciencealert.com/new-melanoma-cancer-vaccine-combo-is-100-effective-in-mice>

“Adjuvant Effect of the Novel TLR1/TLR2 Agonist Diprovocim Synergizes With Anti-PD-L1 to Eliminate Melanoma in Mice,” *Proceedings of the National Academy of Sciences of the United States of America*: <https://www.pnas.org/content/115/37/E8698.short?rss=1>

“A Cancer ‘Vaccine’ Cured 97% of Tumors in Mice. What’s That Mean for People?” *Live Science*: <https://www.livescience.com/62161-cancer-vaccine-trial.html>

© 2019 Manward Press | All Rights Reserved

Manward Press is a financial and lifestyle publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by Manward Press should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties.

The information found in this newsletter may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, 14 West Mount Vernon Place, Baltimore, MD 21201. *Manward Letter* is published monthly for \$149 per year by Manward Press, 14 West Mount Vernon Place, Baltimore, MD 21201, www.manwardpress.com.